During the last decade, the incretin hormone GLP-1 (glucagon like peptide-1) and GIP (gastrointestinal peptide) receptors have received great attention as effective pharmacological targets for counteracting T2D and obesity [[18], [19], [20]]. Here, GIP is linked to obesity disorder.